Company: DMAC
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001437749-25-009696
Chunk: 5

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 5
---
 CEO received a base salary increase of 5% and our CFO received a base salary increase of 6%.                                                                                                                                                                                         
 Our CMO joined DiaMedica in January 2024 and her base salary was set at $425,000.                                                                                                                                                                                                        |
| Short-Term Incentive | Our CEO’s 2024 target short-term incentive opportunity was 50% of base salary and our CMO’s and CFO’s target short-term incentive opportunity was 40% of base salary, which percentages for our CEO and CFO were unchanged from the prior year.                                          |
| Long-Term Incentive  | Our NEOs received stock option awards, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting in 12 equal quarterly installments thereafter. The awards for our CEO and CFO were annual award; whereas the award for our CMO was a new hire award. |
| Other Compensation   | No changes were made to other components of our executive compensation program.                                                                                                                                                                                                          |

<div align='center'>4

301 Carlson Parkway, Suite 210,

Minneapolis, Minnesota 55305

PROXY STATEMENT FOR
ANNUAL GENERAL MEETING OF SHAREHOLDERS
May 15, 2025</div>

The Board of Directors of DiaMedica Therapeutics Inc. is soliciting your proxy for use at the 2025 Annual General Meeting of Shareholders to be held on Thursday, May 15, 2025. The Board of Directors expects to make available to our shareholders beginning on or about March 28, 2025 the Notice of Annual General Meeting of Shareholders, this proxy statement and a form of proxy on the Internet or have these materials sent to shareholders of DiaMedica upon their request.

<div align='center'>GENERAL INFORMATION ABOUT THE MEETING AND VOTING</div>

Date, Time, Place and Purposes of Meeting

The Annual General Meeting of Shareholders of DiaMedica Therapeutics Inc. will be held on Thursday, May 15, 2025, at 9:00 a.m., CDT, at our corporate offices located at 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305, USA, for the purposes set forth in the Notice of Annual General Meeting of Shareholders.

Who Can Vote

Shareholders of record at the close of business on March 18, 2025 will be entitled to notice of and to vote at the meeting or any adjournment thereof.